Compare Google Inc (GOOG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Google Inc trades at $347.45 (market cap $4.24T), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Google Inc is far larger — about 33.2× Vertex Pharmaceuticals Incorporated's market cap, and Google Inc pays a 0.26% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GOOG | VRTX | |
|---|---|---|
Market Cap | $4.24T | $127.55B |
Volume | 13,937,902 | 1,487,944 |
Sector | Media | Health |
52-Week High | $399.06 | $557.96 |
52-Week Low | $237.49 | $407.37 |
Typical Hold Time | 137 Days | 120 Days |
Enterprise Value | $4.13T | $121.68B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $347.37, up 0.81% with strong bullish technical signals. The company demonstrates exceptional fundamental strength with 2025 revenue of $402.84B and net income of $132.17B, maintaining robust profitability margins. Recent earnings beats and aggressive AI investments highlight growth momentum, though capital expenditure spikes have raised free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target.
Alphabet presents a compelling growth story with dominant market positioning and AI leadership, though investors face risks from regulatory scrutiny, intense competition, and significant capital expenditure requirements. The stock's current valuation appears reasonable relative to growth prospects, with technical indicators supporting near-term upside potential toward resistance levels around $350-352.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
